Randomized Trial of Pimecrolimus Cream plus Colchicine Tablets versus Colchicine Tablets in the Treatment of Genital Ulcers in Behcet's Disease

被引:19
作者
Koese, Osman [1 ]
Dinc, Ayhan [2 ]
Simsek, Ismail [2 ]
机构
[1] Gulhane Mil Med Acad, Dept Dermatol, TR-06018 Ankara, Turkey
[2] Gulhane Mil Med Acad, Dept Rheumatol, TR-06018 Ankara, Turkey
关键词
Pimecrolimus; Colchicine; Genital ulcers; Behcet's disease; TOPICAL CALCINEURIN INHIBITORS; MANAGEMENT; MANIFESTATIONS;
D O I
10.1159/000182257
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Recurrent and painful genital ulcers are the hallmark of Behcet's disease. Objective: To determine the efficacy of pimecrolimus (PIM) cream on the pain and healing time of genital ulcers. Methods: A total of 76 patients were randomized to either receive PIM cream plus colchicine (COL) tablets (1-2 g/day) or COL tablets (1-2 g/day) alone for 1 month. Clinical evaluations were performed in 68 patients at the baseline and on the 3rd, 7th, 10th, 14th and 28th days of treatment. Also, genital ulcer pain was evaluated using a verbal pain score at each visit. Safety was monitored through adverse event reporting and laboratory tests. Results: The mean healing time of genital ulcers was shorter in the PIM + COL group (4.2 +/- 1.5 days) than the COL group (4.7 +/- 1.8 days), without statistical significance (p = 0.399). Visual analog scale scores decreased in both groups significantly. Neither of the treatment modalities was found to be superior to the other; however, pain was relieved in 4.2 +/- 0.5 days in PIM + COL group and in 5.5 +/- 1.2 days in COL group in the intention to treat population (p = 0.023). Observed adverse events were transient. Conclusion: Compared to COL alone, COL + PIM cream shortens the pain duration without any significant effect on healing time. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:140 / 145
页数:6
相关论文
共 19 条
[11]   The frequency of scarring after genital ulcers in Behcet's syndrome: a prospective study [J].
Mat, MC ;
Goksugur, N ;
Engin, B ;
Yurdakul, S ;
Yazici, H .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2006, 45 (05) :554-556
[12]   The multiple faces of Behcet's disease and its aetiological factors [J].
Önder, M ;
Gürer, MA .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2001, 15 (02) :126-136
[13]  
ONDER M, 2004, CLIN EXP RHEUMAT S34, V22, pS120
[14]  
SILMAN AJ, 1990, LANCET, V335, P1078
[15]   Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice -: Analysis of a Swiss cohort [J].
Simon, Dagmar ;
Luebbe, Jann ;
Wuethrich, Brunello ;
Wiesner, Alice ;
Weber, M. Monika ;
Laffitte, Emmanuel ;
Anliker, Mark D. ;
Schoeni, Martin H. ;
Braathen, Lasse R. ;
Schmid-Grendelmeier, Peter ;
Bobalj, Nicole Gilgen ;
Schneider, Dirk .
DERMATOLOGY, 2006, 213 (04) :313-318
[16]   Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus [J].
Stuetz, Anton ;
Baumann, Karl ;
Grassberger, Maximilian ;
Wolff, Klaus ;
Meingassner, Josef G. .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2006, 141 (03) :199-212
[17]   Behcet's syndrome: disease manifestations, management, and advances in treatment [J].
Yazici, Hasan ;
Fresko, Izzet ;
Yurdakul, Sebahattin .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2007, 3 (03) :148-155
[18]  
Yurdakul S, 2001, ARTHRITIS RHEUM-US, V44, P2686, DOI 10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO
[19]  
2-H